Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Epidemiology / Impact, vaccines and burden of disease

Vaccine efficacy, effectiveness and herd immunity

14 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Calculate vaccine efficacy from a trial and distinguish it from effectiveness

  • Explain the basic reproduction number R0 and the herd immunity threshold

  • Interpret coverage, breakthrough infections and vaccine impact

Vaccine efficacy (VE)

Vaccine efficacy is the proportional reduction in disease among vaccinated people, measured in a randomised trial under ideal conditions:

VE = (R_u - R_v)/(R_u) = 1 - RR

where R_v and R_u are attack rates (or incidence) in vaccinated and unvaccinated (control) groups.

Worked example

In a trial, 20,000 participants are randomised equally. Over follow-up, 20 vaccinated and 100 placebo participants develop the disease.

  • Attack rate vaccinated = 20/10,000 = 0.2%; placebo = 100/10,000 = 1.0%.
  • RR = 0.2.
  • VE = 1 − 0.2 = 80%.

Vaccine reduces risk of disease by 80% among those vaccinated. The efficacy is relative: it does not say 80% of vaccinated persons are protected; it says the risk is reduced by 80% relative to unvaccinated people. A CI on the RR gives a CI on VE. Regulators often require the lower confidence limit of VE to exceed a threshold such as 30% to 50%.

Efficacy versus effectiveness

EfficacyEffectiveness
SettingRandomised controlled trial, ideal conditionsReal-world use after licensing
DesignRCTCohort, case-control, test-negative design
PopulationSelected, consentedEveryone eligible, including frail
QuestionCan it work?Does it work in practice?

Effectiveness is usually a little lower because of imperfect cold chain, delays, missed doses and comorbidity. It is measured in observational studies, which must control for confounding: vaccinated people differ from unvaccinated people (more health-seeking).

The test-negative design

Among patients with symptoms who are tested, cases are test-positive and controls are test-negative. VE = 1 - OR, where OR compares vaccination odds in cases against controls. It is cheap, quick and widely used for influenza, rotavirus and COVID-19, but it requires careful selection of care-seekers.

Herd immunity and R0

The basic reproduction number R0 is the average number of secondary cases from one infectious case in a completely susceptible population. If R_0 > 1, an epidemic grows; if < 1, it dies out.

051015Typical R0 (approximate)1.3Seasonal flu (1.3)2.5COVID-19 original (2.5)6Polio (6)15Measles (15)
Approximate R0 values. Estimates vary with population density and contact patterns.

The herd immunity threshold

The fraction of the population that must be immune to stop sustained spread:

H = 1 - (1)/(R_0)

With imperfect vaccines, the required coverage is H / VE.

Applying the formula

  • Measles, R_0 = 15: H = 1 - 1/15 = 93.3\%. With a vaccine of efficacy 95% after two doses, coverage must reach 93.3/0.95 = 98\%. That is why measles resurges when coverage falls below about 95%.
  • A pathogen with R_0 = 2.5: H = 60\%; with a 90% effective vaccine, coverage needed is 60/0.9 = 67\%.

Herd immunity protects those who cannot be vaccinated (infants, immunocompromised) but depends on uniform coverage: pockets of low coverage allow outbreaks even if the national average is high.

Immunisation programme indicators

  • Coverage = vaccinated ÷ eligible children (DPT3, measles, BCG), from administrative data and surveys.
  • Drop-out rate = (first dose − last dose) ÷ first dose; indicates access versus utilisation problems.
  • Zero-dose children: those who have received no routine vaccine.
  • Vaccine impact: change in disease incidence, hospital admissions and deaths after introduction.

Common errors

Interpreting 'VE 90%' as 'each person has a 10% chance of infection'; comparing VE between trials with different case definitions or seasons; ignoring waning protection over time; confusing doses with fully vaccinated people; assuming that high national coverage guarantees local herd immunity.

Summary

  • VE = 1 − RR; it measures the proportional reduction in disease among the vaccinated.

  • Efficacy is measured in trials; effectiveness in real-world observational studies, including the test-negative design.

  • R0 above 1 means growth; the herd immunity threshold is 1 − 1/R0.

  • With an imperfect vaccine, required coverage = threshold ÷ VE.

  • Local pockets of low coverage can support outbreaks despite high national coverage.

Check your understanding

Question 1
1

Attack rates are 1% in placebo and 0.3% in vaccinated. VE is:

Question 2
2

A disease with R0 = 4 has a herd immunity threshold of:

Question 3
3

The test-negative design estimates vaccine effectiveness by comparing vaccination odds in:

Question 4
4

Vaccine effectiveness is usually lower than efficacy because of:

Question 5
5

A national DPT3 coverage of 90% could still allow outbreaks because of:

Question 6
6

Drop-out rate between first and third doses measures:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Attributable risk and population impactMortality, life expectancy and the burden of disease (DALYs)